Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 6.11.2017 | EN | Official Journal of the European Union | C 374/26 |

---

Judgment of the General Court of 21 September 2017 — Novartis v EUIPO — Meda (Zymara)

(Case T-214/15)[(1)](#ntr1-C_2017374EN.01002602-E0001)

((EU trade mark - Opposition proceedings - Application for the EU word mark Zymara - Earlier EU word mark FEMARA - Relative ground for refusal - Article 8(1)(b) of Regulation (EC) No 207/2009 - Article 75 of Regulation No 207/2009 - Article 76(1) of Regulation No 207/2009))

(2017/C 374/39)

Language of the case: English

Parties

Applicant: Novartis AG (Basle, Switzerland) (represented by M. Douglas, lawyer)

Defendant: European Union Intellectual Property Office (represented by H. O’Neill, acting as Agent)

Other party to the proceedings before the Board of Appeal of EUIPO: Meda AB (Solna, Sweden)

Re:

Action brought against the decision of the Fifth Board of Appeal of EUIPO of 6 February 2015 (Case R 550/2014-5) relating to opposition proceedings between Novartis and Meda.

Operative part of the judgment

The Court:

|  |  |
| --- | --- |
| 1. | Dismisses the action; |

|  |  |
| --- | --- |
| 2. | Orders Novartis AG to pay the costs. |

---

[Top](#document1)